The increase in price target by Citigroup, despite maintaining a Neutral rating, suggests an improved outlook for Tandem Diabetes Care's stock. This adjustment reflects a positive sentiment towards the company's future performance and could lead to increased investor interest, potentially driving the stock price up in the short term.